DENVER — Early data for a new vaccine for pancreatic cancer is generating some hope among patients, researchers and doctors.

An 'off-the-shelf' vaccine may help prevent or delay cancer recurrence in people with hard-to-treat colorectal or pancreatic ...

A new study reveals promising results for a vaccine targeting colorectal and pancreatic cancers. Researchers from the ...

An off-the-shelf cancer vaccine that targets KRAS mutations induced T-cell responses and was associated with impressive ...

In an early trial, a one-size-fits-all vaccine showed promise in preventing hard-to-treat pancreatic cancers from coming back ...

New Phase I trial data finds that people who responded to ELI-002 survived longer and stayed cancer-free longer than usual.

Cancer rates in 2025 are predicted to exceed the previous year's statistics, with one-in-three men and women both at risk of contracting the disease.

Dr. Zev Wainberg of UCLA recently spoke with CURE about trial results concerning the cancer vaccine ELI-002 2P.

Researchers found patients with pancreatic cancer and bowel cancer survived more than two years after receiving the vaccine ...

A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back, a small ...

A new vaccine designed to combat cancer cells in patients with colorectal and pancreatic cancer showed promising results in ...

A new 'off-the-shelf' vaccine with the catchy name ELI-002 2P offers fresh hope for individuals affected by these deadly ...